What is HC Wainwright's Forecast for VIR FY2028 Earnings?

Key Points

• HC Wainwright lowered its FY2028 EPS forecast for Vir Biotechnology to a loss of $1.71 per share from $1.70, while projecting losses of $1.26 in FY2029 and $0.29 in FY2030.
• Despite the revised estimates, HC Wainwright maintained a Buy rating and $22 price target; analysts overall rate the stock “Moderate Buy” with a consensus target of $21.86.
• Vir recently exceeded quarterly expectations, reporting $0.47 EPS versus a $0.33 consensus and $238.95 million in revenue, up sharply year over year.

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Stock analysts at HC Wainwright decreased their FY2028 earnings estimates for Vir Biotechnology in a research report issued to clients and investors on Wednesday, October 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($1.71) for the year, down from their previous estimate of ($1.70). HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Vir Biotechnology's current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Vir Biotechnology's FY2029 earnings at ($1.26) EPS and FY2030 earnings at ($0.29) EPS.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.14. The business had revenue of $238.95 million for the quarter, compared to analyst estimates of $135.88 million. The business's revenue was up 19582.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.80) earnings per share.

A number of other equities research analysts also recently weighed in on VIR. Raymond James Financial reiterated a "strong-buy" rating on shares of Vir Biotechnology in a report on Monday, September 28th. Zacks Research cut Vir Biotechnology from a "hold" rating to a "strong sell" rating in a report on Tuesday. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research report on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Finally, Wall Street Zen upgraded shares of Vir Biotechnology from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Vir Biotechnology presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.86.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $11.12 on Friday. Vir Biotechnology has a one year low of $4.82 and a one year high of $11.94. The stock's 50-day moving average is $10.41 and its 200 day moving average is $9.78. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -5.98 and a beta of 1.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VIR. ADAR1 Capital Management LLC acquired a new stake in shares of Vir Biotechnology in the 2nd quarter worth about $25,034,000. Parkman Healthcare Partners LLC acquired a new position in Vir Biotechnology during the 2nd quarter valued at about $4,843,000. ARCH Venture Management LLC acquired a new position in Vir Biotechnology during the 2nd quarter valued at about $129,353,521. Pictet Asset Management Holding SA increased its holdings in Vir Biotechnology by 10,878.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company's stock worth $13,268,000 after purchasing an additional 1,467,340 shares in the last quarter. Finally, Candriam S.C.A. increased its holdings in Vir Biotechnology by 10.1% during the 1st quarter. Candriam S.C.A. now owns 1,135,763 shares of the company's stock worth $10,176,000 after purchasing an additional 104,100 shares in the last quarter. Institutional investors own 65.32% of the company's stock.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Higher price target and Buy rating: HC Wainwright raised its price target for Vir Biotechnology from $20 to $22 and reiterated a Buy rating, implying substantial potential upside from the current level. The upgrade reflects optimism about Vir’s pipeline and upcoming clinical catalysts. Vir Biotechnology stock gained before SOLSTICE data
• Positive Sentiment: New chief medical officer: Vir appointed David Liu as chief medical officer, strengthening its clinical-development leadership ahead of important data readouts. The appointment may improve investor confidence in execution across the company’s infectious-disease programs. Vir appoints David Liu as chief medical officer
• Neutral Sentiment: SOLSTICE data is the key catalyst: Upcoming Phase 2 SOLSTICE results in HDV could materially reshape Vir’s investment narrative. Positive efficacy or safety data could support the pipeline and valuation, while disappointing results could increase development and financing concerns. No results have been reported yet. Upcoming SOLSTICE Phase 2 HDV data
• Neutral Sentiment: A financial comparison of uniQure and Vir Biotechnology provides sector context but does not appear to introduce a new company-specific catalyst. uniQure and Vir Biotechnology financial survey
• Negative Sentiment: Zacks downgrade: Zacks Research lowered Vir Biotechnology from “Hold” to “Strong Sell.” The downgrade is likely weighing on the stock because it reinforces concerns about the company’s continuing losses and reliance on future clinical success. Vir Biotechnology stock rating lowered by Zacks Research

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing treatments and preventive therapies for serious infectious diseases. The company uses immunologic insights, antibody technology, cellular approaches and other scientific platforms to address diseases in which the immune system plays a central role.

Vir's research and development programs have included therapies for chronic hepatitis B, influenza, human immunodeficiency virus (HIV) and COVID-19. Its pipeline has included investigational antibody and immunomodulatory candidates such as tobevibart and elebsiran for hepatitis B, as well as programs designed to prevent or treat other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.